FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380998031> ?p ?o ?g. }

• W4380998031 abstract "The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. The safety and immunogenicity after 28 days of a single Ad26.COV2.S booster dose given at different intervals after 2 doses of BBIBP-CorV are presented. This open-label phase 1/2 trial was conducted in healthy adults in Thailand who had completed 2-dose primary vaccination with BBIBP-CorV. Participants received a single booster dose of Ad26.COV2.S (5 × 1010 virus particles) 90–240 days (Group A1; n = 360) or 45–75 days (Group A2; n = 66) after the second BBIBP-CorV dose. Safety and immunogenicity were assessed over 28 days. Binding IgG antibodies to the full-length pre-fusion Spike and anti-nucleocapsid proteins of SARS-CoV-2 were measured by enzyme-linked immunosorbent assay. The SARS-CoV-2 pseudovirus neutralization assay and live virus microneutralization assay were used to quantify the neutralizing activity of antibodies against ancestral SARS-CoV-2 (Wuhan-Hu-1) and the delta (B.1.617.2) and omicron (B.1.1.529/BA.1 and BA.2) variants. The cell-mediated immune response was measured using a quantitative interferon (IFN)-γ release assay in whole blood. Solicited local and systemic adverse events (AEs) on days 0–7 were mostly mild, as were unsolicited vaccine-related AEs during days 0–28, with no serious AEs. On day 28, anti-Spike binding antibodies increased from baseline by 487- and 146-fold in Groups A1 and A2, and neutralizing antibodies against ancestral SARS-CoV-2 by 55- and 37-fold, respectively. Humoral responses were strongest against ancestral SARS-CoV-2, followed by the delta, then the omicron BA.2 and BA.1 variants. T-cell–produced interferon-γ increased approximately 10-fold in both groups. A single heterologous Ad26.COV2.S booster dose after two BBIBP-CorV doses was well tolerated and induced robust humoral and cell-mediated immune responses measured at day 28 in both interval groups. Clinical Trials Registration. NCT05109559." @default.
• W4380998031 created "2023-06-17" @default.
• W4380998031 creator A5005987903 @default.
• W4380998031 creator A5017104549 @default.
• W4380998031 creator A5027042022 @default.
• W4380998031 creator A5028706639 @default.
• W4380998031 creator A5029953945 @default.
• W4380998031 creator A5034965946 @default.
• W4380998031 creator A5037956991 @default.
• W4380998031 creator A5042464592 @default.
• W4380998031 creator A5043517285 @default.
• W4380998031 creator A5044946797 @default.
• W4380998031 creator A5045965975 @default.
• W4380998031 creator A5058440042 @default.
• W4380998031 creator A5065207799 @default.
• W4380998031 creator A5065776945 @default.
• W4380998031 creator A5066195722 @default.
• W4380998031 creator A5070420979 @default.
• W4380998031 creator A5075669592 @default.
• W4380998031 creator A5075945025 @default.
• W4380998031 date "2023-06-01" @default.
• W4380998031 modified "2023-10-18" @default.
• W4380998031 title "Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial" @default.
• W4380998031 cites W3027138240 @default.
• W4380998031 cites W3092766467 @default.
• W4380998031 cites W3131688063 @default.
• W4380998031 cites W3133128009 @default.
• W4380998031 cites W3137970801 @default.
• W4380998031 cites W3153508314 @default.
• W4380998031 cites W3169082905 @default.
• W4380998031 cites W3171227933 @default.
• W4380998031 cites W3176239731 @default.
• W4380998031 cites W3179399516 @default.
• W4380998031 cites W3189762432 @default.
• W4380998031 cites W3190786637 @default.
• W4380998031 cites W3192691285 @default.
• W4380998031 cites W3202826390 @default.
• W4380998031 cites W3211051404 @default.
• W4380998031 cites W4200252704 @default.
• W4380998031 cites W4200531314 @default.
• W4380998031 cites W4205240144 @default.
• W4380998031 cites W4205283268 @default.
• W4380998031 cites W4206109560 @default.
• W4380998031 cites W4206906464 @default.
• W4380998031 cites W4207066590 @default.
• W4380998031 cites W4210272290 @default.
• W4380998031 cites W4210450230 @default.
• W4380998031 cites W4210467545 @default.
• W4380998031 cites W4210792795 @default.
• W4380998031 cites W4212835565 @default.
• W4380998031 cites W4220886379 @default.
• W4380998031 cites W4221103003 @default.
• W4380998031 cites W4223499046 @default.
• W4380998031 cites W4223571845 @default.
• W4380998031 cites W4226229183 @default.
• W4380998031 cites W4226310502 @default.
• W4380998031 cites W4226343533 @default.
• W4380998031 cites W4226376477 @default.
• W4380998031 cites W4229037579 @default.
• W4380998031 cites W4281291961 @default.
• W4380998031 cites W4283708032 @default.
• W4380998031 cites W4283766061 @default.
• W4380998031 cites W4284885723 @default.
• W4380998031 cites W4308774038 @default.
• W4380998031 cites W4360871696 @default.
• W4380998031 cites W4376849664 @default.
• W4380998031 doi "https://doi.org/10.1016/j.vaccine.2023.06.043" @default.
• W4380998031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37344265" @default.
• W4380998031 hasPublicationYear "2023" @default.
• W4380998031 type Work @default.
• W4380998031 citedByCount "2" @default.
• W4380998031 countsByYear W43809980312023 @default.
• W4380998031 crossrefType "journal-article" @default.
• W4380998031 hasAuthorship W4380998031A5005987903 @default.
• W4380998031 hasAuthorship W4380998031A5017104549 @default.
• W4380998031 hasAuthorship W4380998031A5027042022 @default.
• W4380998031 hasAuthorship W4380998031A5028706639 @default.
• W4380998031 hasAuthorship W4380998031A5029953945 @default.
• W4380998031 hasAuthorship W4380998031A5034965946 @default.
• W4380998031 hasAuthorship W4380998031A5037956991 @default.
• W4380998031 hasAuthorship W4380998031A5042464592 @default.
• W4380998031 hasAuthorship W4380998031A5043517285 @default.
• W4380998031 hasAuthorship W4380998031A5044946797 @default.
• W4380998031 hasAuthorship W4380998031A5045965975 @default.
• W4380998031 hasAuthorship W4380998031A5058440042 @default.
• W4380998031 hasAuthorship W4380998031A5065207799 @default.
• W4380998031 hasAuthorship W4380998031A5065776945 @default.
• W4380998031 hasAuthorship W4380998031A5066195722 @default.
• W4380998031 hasAuthorship W4380998031A5070420979 @default.
• W4380998031 hasAuthorship W4380998031A5075669592 @default.
• W4380998031 hasAuthorship W4380998031A5075945025 @default.
• W4380998031 hasBestOaLocation W43809980311 @default.
• W4380998031 hasConcept C12590561 @default.
• W4380998031 hasConcept C14086860 @default.
• W4380998031 hasConcept C159047783 @default.
• W4380998031 hasConcept C159654299 @default.
• W4380998031 hasConcept C197934379 @default.
• W4380998031 hasConcept C203014093 @default.
• W4380998031 hasConcept C22070199 @default.
• W4380998031 hasConcept C2776090121 @default.

• next